Panobinostat, sold as Farydak, is a hydroxamic acid compound that works as a non-selective histone deacetylase inhibitor, blocking multiple HDAC enzymes at once. This disrupts the normal packaging of DNA inside cancer cells and pushes them toward programmed cell death through several overlapping pathways. It is used mainly to treat multiple myeloma in adults who have already received at least two earlier lines of treatment, given in combination with bortezomib and dexamethasone. The United States approved it in February 2015 and the European Union followed in August 2015, both under an orphan drug designation reflecting its development for a relatively rare cancer. The medication was withdrawn from the United States market in March 2022.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration First Approved / Isolated Year Connections
Sources
1. Panobinostat (Wikipedia)
Lead section, approval-status statementQuote, Lead section, approval-status statement
Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015.
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. Panobinostat (Wikipedia)
WikipediaInfobox drug, routes_of_administrationQuote, Infobox drug, routes_of_administration
By mouth
4. Drugs.com: Farydak (panobinostat) FDA Approval History
FDA Approval HistoryQuote, FDA Approval History
Farydak (panobinostat) was first approved by the FDA on February 23, 2015
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.